Diagnostic Performance of Prostate Multiparametric Magnetic Resonance Imaging in African-American Men



      To compare test performance of multiparametric magnetic resonance imaging (mpMRI) for detection of prostate cancer (PCa) in African-American men (AAM) and white men (WM) using the Prostate Imaging Reporting and Data System in unmatched groups as well as a cohort matched for clinical factors.


      We examined our database of men who underwent prostate mpMRI prior to biopsy between October 2014 and June 2017 (n = 601; 60 AAM, 541 WM). Test performance was defined using Prostate Imaging Reporting and Data System classification 4 or 5 considered test positive and Gleason grade group 2 or greater from any biopsy core considered outcome positive. A subset analysis was performed using a propensity score caliper matching algorithm to match AAM to WM in a 1:2 ratio using the variables age, PSA, and PSA density.


      No significant differences in test performance were found with similar sensitivity (86.7% vs 83.6, P = 1.00), specificity (45.9% vs 49.1%, P = .71), positive predictive value (50.0% vs 46.9%), and negative predictive value (85.0% vs 84.8%, P = 1.00) for AAM and WM. Similar results were noted in our matched comparison. The rate of upgrading between targeted and systematic biopsy cores did not statistically differ between AAM and WM in both unmatched (12.2% vs. 15.8%, P = .66) and matched (12.2% vs 12.8%, P = .92) comparisons.


      Our findings provide supporting evidence that AAM have similar outcomes to WM in PCa detection using mpMRI. We suggest that mpMRI should not be withheld or offered preferentially on the basis of race when used for the detection of PCa.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Urology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Siegel RL
        • Miller KD
        • Jemal A
        Cancer statistics, 2019.
        CA Cancer J Clin. 2019; 69: 7-34
        • Smith ZL
        • Eggener SE
        • Murphy AB
        African-American prostate cancer disparities.
        Curr Urol Rep. 2017; 18: 81
        • Nettey OS
        • Walker AJ
        • Keeter MK
        • et al.
        Self-reported Black race predicts significant prostate cancer independent of clinical setting and clinical and socioeconomic risk factors.
        Urol Oncol. 2018; 36 (501 e1-e8)
        • Kasivisvanathan V
        • Rannikko AS
        • Borghi M
        • et al.
        MRI-targeted or standard biopsy for prostate-cancer diagnosis.
        N Engl J Med. 2018; 378: 1767-1777
        • Liu W
        • Patil D
        • Howard DH
        • et al.
        Adoption of prebiopsy magnetic resonance imaging for men undergoing prostate biopsy in the United States.
        Urology. 2018; 117: 57-63
        • Weaver JK
        • Kim EH
        • Vetter JM
        • et al.
        Prostate magnetic resonance imaging provides limited incremental value over the memorial sloan kettering cancer center preradical prostatectomy nomogram.
        Urology. 2018; 113: 119-128
        • Weinreb JC
        • Barentsz JO
        • Choyke PL
        • et al.
        PI-RADS prostate imaging - reporting and data system: 2015, version 2.
        Eur Urol. 2016; 69: 16-40
        • Polanec S
        • Helbich TH
        • Bickel H
        • et al.
        Head-to-head comparison of PI-RADS v2 and PI-RADS v1.
        Eur J Radiol. 2016; 85: 1125-1131
        • Bhat NR
        • Vetter JM
        • Andriole GL
        • Shetty AS
        • Ippolito JE
        • Kim EH
        Magnetic resonance imaging-defined prostate-specific antigen density significantly improves the risk prediction for clinically significant prostate cancer on biopsy.
        Urology. 2018; 126: 152-157
        • Carter HB
        • Albertsen PC
        • Barry MJ
        • et al.
        Early detection of prostate cancer: AUA Guideline.
        J Urol. 2013; 190: 419-426
        • Mottet N
        • Bellmunt J
        • Bolla M
        • et al.
        EAU-ESTRO-SIOG guidelines on prostate cancer. Part 1: screening, diagnosis, and local treatment with curative intent.
        Eur Urol. 2017; 71: 618-629
        • Butler S
        • Muralidhar V
        • Chavez J
        • et al.
        Active surveillance for low-risk prostate cancer in black patients.
        N Engl J Med. 2019; 380: 2070-2072
        • Miller EA
        • Pinsky PF
        • Black A
        • Andriole GL
        • Pierre-Victor D
        Secondary prostate cancer screening outcomes by race in the Prostate, Lung, Colorectal, and Ovarian (PLCO) Screening Trial.
        Prostate. 2018; 78: 830-838
        • Devaney JM
        • Wang S
        • Furbert-Harris P
        • et al.
        Genome-wide differentially methylated genes in prostate cancer tissues from African-American and Caucasian men.
        Epigenetics. 2015; 10: 319-328
        • Powell IJ
        • Dyson G
        • Land S
        • et al.
        Genes associated with prostate cancer are differentially expressed in African-American and European-American men.
        Cancer Epidemiol Biomarkers Prev. 2013; 22: 891-897
        • Parekh DJ
        • Punnen S
        • Sjoberg DD
        • et al.
        A multi-institutional prospective trial in the USA confirms that the 4Kscore accurately identifies men with high-grade prostate cancer.
        Eur Urol. 2015; 68: 464-470
        • Kim EH
        • Andriole GL
        • Crawford ED
        • et al.
        Detection of high grade prostate cancer among PLCO participants using a prespecified 4-Kallikrein Marker Panel.
        J Urol. 2017; 197: 1041-1047
        • O'Malley PG
        • Nguyen DP
        • Al Hussein Al Awamlh B
        • et al.
        Racial variation in the utility of urinary biomarkers PCA3 and T2ERG in a large multicenter study.
        J Urol. 2017; 198: 42-49
        • Shin T
        • Smyth TB
        • Ukimura O
        • et al.
        Detection of prostate cancer using magnetic resonance imaging/ultrasonography image-fusion targeted biopsy in African-American men.
        BJU Int. 2017; 120: 233-238
        • Walton E
        • Yaguchi G
        • Keeley J
        • et al.
        Effect of lesion location on prostate cancer detection rate with magnetic resonance imaging targeted biopsy in African Americans.
        J Urol. 2019; 201: 503-509